Summit Therapeutics (SUMM) Posts Quarterly Earnings Results, Misses Estimates By $2.00 EPS

Summit Therapeutics (LON:SUMM) issued its earnings results on Tuesday. The company reported GBX (10) (($0.13)) earnings per share (EPS) for the quarter, missing the consensus estimate of GBX (8) (($0.10)) by GBX (2) (($0.03)), Bloomberg Earnings reports.

Shares of LON SUMM traded down GBX 1 ($0.01) during midday trading on Thursday, hitting GBX 18 ($0.24). The stock had a trading volume of 23,875 shares, compared to its average volume of 34,608. Summit Therapeutics has a 52 week low of GBX 140 ($1.83) and a 52 week high of GBX 269.70 ($3.52).

In related news, insider Leopoldo Zambeletti sold 11,358 shares of the stock in a transaction that occurred on Wednesday, October 24th. The shares were sold at an average price of GBX 28 ($0.37), for a total transaction of £3,180.24 ($4,155.55).

TRADEMARK VIOLATION NOTICE: “Summit Therapeutics (SUMM) Posts Quarterly Earnings Results, Misses Estimates By $2.00 EPS” was first published by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at

Summit Therapeutics Company Profile

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Recommended Story: How are the companies in the S&P 500 selected?

Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply